The U.S.-based company, founded in 2000 and later acquired by Pfizer in 2008, focuses on developing a range of small molecule Hsp90 inhibitors for various diseases, including cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases like Alzheimer's. In addition, Serenex is actively working on SNX-1012, an oral mucositis product designed for solid tumor patients. With a primary focus on oncology, Serenex is dedicated to advancing the field of drug development and discovery, particularly in cancer, inflammation, and other disease areas.